Every 8-K that Sanara MedTech Inc. (SMTI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SMTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SMTI filings page.
Sanara MedTech Inc. reported second quarter 2026 net revenue of $28.1 million, up 9% from $25.8 million a year earlier, driven by an 11% increase in soft tissue repair product sales, partially offset by lower bone fusion product revenue. Gross margin rose to 93%, with gross profit of $26.2 million. However, higher selling, general and administrative expenses, including about $1.1 million of legal and advisory costs for corporate strategic initiatives, and increased interest expense led to operating income declining to $1.8 million from $2.5 million and a net loss from continuing operations of $0.4 million, versus net income of $0.5 million in 2025.
For the first six months of 2026, net revenue increased 14% to $55.9 million, operating income improved to $4.4 million from $3.3 million, and Adjusted EBITDA rose to $9.3 million from $7.4 million. Net loss from continuing operations was $13,457, essentially breakeven per share. Cash and cash equivalents were $15.4 million and long-term debt $46.5 million at June 30, 2026, and net cash used in operating activities was $0.4 million. Management highlighted a pending transformational agreement under which Sanara is expected to be acquired by MIMEDX, subject to customary closing conditions, and noted continued focus on expanding its surgical product portfolio, including the planned first-quarter 2027 introduction of OsStic.
Sanara MedTech Inc. amended a prior current report to correct termination fee amounts in its merger agreement with MiMedx Group, Inc., lowering Sanara’s cash termination fee obligation to $9,660,336.00 and increasing MiMedx’s reverse termination fee to $22,540,785.00.
Under the Agreement and Plan of Merger, a MiMedx subsidiary will merge into Sanara, which will survive as a wholly owned subsidiary of MiMedx. At closing, each share of Sanara common stock (other than excluded or appraisal shares) will be converted into $33.00 in cash plus 0.4735 shares of MiMedx common stock, with the stock portion valued at $2.00 per share based on a five-day average. Sanara equity awards will be cashed out and/or converted based on this merger consideration. Closing is subject to stockholder approval, antitrust and other regulatory clearances, effectiveness of an S-4 registration, Nasdaq listing of MiMedx shares, and customary conditions including absence of a Material Adverse Effect. A Voting Agreement covers holders representing about 38.9% of Sanara’s voting power. If completed, Sanara shares will be delisted from Nasdaq and deregistered.
Sanara MedTech Inc. agreed to be acquired by MiMedx Group through a definitive Agreement and Plan of Merger under which Mustang Merger Sub will merge into Sanara, making Sanara a wholly owned MiMedx subsidiary. For each share of Sanara common stock, holders are entitled at closing to receive $33.00 in cash plus 0.4735 shares of MiMedx common stock, valued at $2.00 per share, for total merger consideration of $35 per Sanara share and an implied enterprise value of approximately $350 million, a 46% premium to Sanara’s 30‑day volume‑weighted average price.
The transaction is unanimously approved by both boards and supported by a Voting Agreement under which specified Sanara stockholders holding about 38.9% of the voting power agree to vote for the deal and against alternative proposals. Closing remains subject to Sanara stockholder approval, expiration of Hart‑Scott‑Rodino and other antitrust and foreign investment waiting periods, SEC effectiveness of MiMedx’s Form S‑4, Nasdaq listing of the MiMedx shares to be issued, absence of injunctions and of any Material Adverse Effect, and other customary conditions. Either party may terminate under agreed circumstances; Sanara would owe MiMedx a $22,540,785 termination fee in certain competing‑bid or failed‑vote scenarios, while MiMedx would owe Sanara $9,660,336 if it fails to close when required. MiMedx expects to finance the cash portion through cash on hand and a new $300 million term loan. Upon completion, Sanara’s stock will be delisted from Nasdaq and deregistered.
Sanara MedTech Inc. reported the results of its annual shareholder meeting, where 6,701,593 shares of common stock were represented. Shareholders elected nine directors, each to serve a one-year term ending at the 2027 annual meeting.
Investors also ratified Weaver and Tidwell, L.L.P. as independent auditor for the year ending December 31, 2026, and approved on an advisory basis the compensation of named executive officers. In a separate advisory vote, shareholders favored holding future say-on-pay votes every three years, and the board adopted this frequency until the expected vote at the 2029 annual meeting.
Sanara MedTech Inc. has terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc., effective immediately on June 2, 2026. The move is tied to a strategic shift toward soft tissue repair and bone fusion products for the surgical market.
The agreement, originally effective March 1, 2023, had engaged Catalyst for transaction and strategic advisory services. Catalyst is affiliated with the Company’s chairman and, with its affiliates, beneficially owns more than 5% of Sanara’s common stock. No fee or penalty was paid for the termination, and covenants on indemnification and confidentiality remain in force.
Sanara MedTech Inc. reported strong first quarter 2026 results with higher growth and a swing to profitability. Net revenue rose 19% to $27.8 million, driven mainly by a 21% increase in soft tissue repair product sales, while bone fusion revenue was slightly lower.
Gross profit reached $25.9 million with a 93% margin, up from 92%. Operating income more than tripled to $2.6 million. Net income from continuing operations was $0.4 million, or $0.04 per diluted share, compared with a loss a year earlier, and total net income was $0.46 million. Adjusted EBITDA increased 58% to $4.3 million, reflecting operating leverage despite higher selling and marketing costs.
Sanara ended March 31, 2026 with $13.6 million in cash and $46.2 million of long-term debt. The company guided second quarter 2026 net revenue to $28.5–$29.5 million (10–14% growth) and reaffirmed full-year 2026 net revenue guidance of $116–$121 million, implying 13–17% growth over 2025.
Sanara MedTech Inc. reported strong 2025 growth with net revenue of $103.1 million, up 19% from 2024, and reaffirmed 2026 revenue guidance of $116–$121 million, implying 13%–17% additional growth. Revenue expansion was led by soft tissue repair products, especially CellerateRX Surgical, and supported by a broader distributor and facility network.
Adjusted EBITDA rose to $17.0 million from $9.1 million, and operating cash flow improved to $6.8 million. Gross margin reached 93% in Q4 2025. However, a strategic realignment and the discontinuation of Tissue Health Plus drove a $26.5 million noncash impairment and a full-year net loss of $37.6 million. Management highlights a focused surgical business, higher R&D investment, and long-term growth ambitions in the surgical market.
Sanara MedTech Inc. filed a current report to furnish an investor presentation it plans to use with investors and analysts, including at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026. The presentation, attached as Exhibit 99.1, outlines the company’s priorities, strategy and anticipated revenue for fiscal 2026.
The company notes this information is being furnished under Regulation FD, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other Securities Act or Exchange Act filings.
Sanara MedTech Inc. filed a current report to let investors know it has released a press release with certain preliminary financial results for the fourth quarter and full year 2025. The company states that this press release, dated January 23, 2026, is provided as an exhibit to the report and is incorporated by reference.
The company also clarifies that the information in this report, including the press release, is being furnished rather than filed, which means it is not subject to certain liability provisions of the securities laws or automatically incorporated into other securities filings unless specifically referenced.
Sanara MedTech Inc. (SMTI) reported that it is furnishing an investor presentation as Exhibit 99.1 to a current report on Form 8-K. The presentation will be used in meetings with investors and analysts, including during the company’s appearance at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025. The deck outlines the company’s priorities and strategy for the 2026 fiscal year and is intended to be read together with its other SEC filings and public announcements. The company states that this information is being furnished under Regulation FD, is not deemed “filed” under the Exchange Act, and is not automatically incorporated by reference into other Securities Act or Exchange Act filings.
Sanara MedTech Inc. (SMTI) reported that it issued a press release with financial results for the quarter ended September 30, 2025. The company furnished this information on a Form 8-K dated November 12, 2025, with the press release included as Exhibit 99.1.
The submission states that the press release and related information are furnished and not deemed “filed” under Section 18 of the Exchange Act, which limits associated liabilities. SMTI’s common stock trades on the Nasdaq Capital Market under the symbol SMTI.
Sanara MedTech Inc. (SMTI) disclosed a business update, announcing a strategic realignment that includes discontinuing operations of its Tissue Health Plus. The company communicated this decision via a press release issued on November 11, 2025, which is furnished as Exhibit 99.1.
The press release is provided for information purposes and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference into other filings unless expressly stated.
Sanara MedTech Inc. announced a leadership transition and accounting role change. The Board appointed Seth D. Yon as President and Chief Executive Officer, and as a director, effective September 15, 2025, expanding the Board from eight to nine members. Yon, a long-time commercial leader at the company, receives a base salary of $600,000, is eligible for annual equity and cash bonuses of up to 100% of salary each, and will receive a one-time restricted stock grant valued at $1.0 million that vests over three years.
Current CEO Ronald T. Nixon will resign from the CEO role on the effective date but will continue as Executive Chairman of the Board. His resignation is stated as not being due to any disagreement with the company, and his compensation will shift to director and Executive Chairman retainers. The Board also designated Ashley Mackey, the company’s Controller, as principal accounting officer, while Elizabeth B. Taylor remains Chief Financial Officer.
Sanara MedTech Inc. announced its financial results for the quarter ended June 30, 2025 via a press release furnished as Exhibit 99.1 to this Current Report. The report explicitly states the press release is furnished rather than filed, and therefore the exhibit is not subject to Section 18 liability nor automatically incorporated by reference into other securities filings unless expressly stated.
The body of the Current Report contains no financial figures or performance metrics, so readers must consult Exhibit 99.1 for the company’s detailed results and any quantitative disclosures.
Sanara MedTech (ticker SMTI) is listed on the Nasdaq Capital Market and identifies its principal executive offices in Fort Worth, Texas.